Total Funding
63
56
Total FundingSeries A raised
Growth Score
-2 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
76987
New Health Sciences develops a technology to extend the shelf life of refrigerated red blood cells using novel storage methods.
- Martin Cannon: President & CEOPast Role: Hemanext, Co- Founder, President & CEO
About the Company
New Health Sciences is developing Hemanext, a technology designed to improve the safety and efficacy of transfusion therapy through novel storage methods potentially extending the shelf life of refrigerated red blood cells while improving their quality across the storage cycle. NHSi has financed development of the Hemanext technology through
private investor funding and a series of NIH SBIR grants.
